Will@ I see and understand - You don't want to speculate to much - but prefers to look at 'what is reality'.
And reality right now is 'Still full steam ahead in USA - 800 sales reps - DTS etc'.
Europe GIA - which many says could be 'suicide for the company' - something has to happen to Get into Europe 'Full Speed' ! ------------------------------
As you say 'from here on' It's all about sales numbers' - and that is obviously why company has decided to - 'Go full steam ahead' in US (despite generic ANDAs).
The filosofi has to be 'Get as much power in sales as possible' before generic's find their feets in the market - and that could (given the circumstances) actually be the right strategy.
Thanks again Will - later !
Jasbg
PS. As It has been ever since R-I - AMRN investors - 'Waiting' for that message of BO / Serios Partnership with BP - that could take both Vascepa - and SP to were it should be in - helping CDV patients - and rewarding Investors :)
News 
Market Data 
Discover 
